QU

QuantaMatrix Incorporated

IVD specialist in rapid antimicrobial susceptibility testing for critical infections like sepsis.

317690 | KO

Overview

Corporate Details

ISIN(s):
KR7317690006
LEI:
Country:
South Korea
Address:
서울특별시 금천구 가산디지털1로 131 B동 16층(가산동, 비와이씨하이시티), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

QuantaMatrix Inc. is an in-vitro diagnostics (IVD) company specializing in innovative solutions for clinical microbiology. The company develops and manufactures medical devices that utilize proprietary technologies, including time-lapse microscopic imaging and microfluidics, to accelerate pathogen identification and antimicrobial susceptibility testing (AST). Its primary focus is on critical infections such as sepsis, with its dRAST™ (direct Rapid Antimicrobial Susceptibility Test) system designed to provide results significantly faster than conventional methods. By enabling quicker and more accurate diagnoses, QuantaMatrix aims to improve patient outcomes, facilitate timely antibiotic treatment, and help combat antimicrobial resistance. The company's platforms also serve molecular and immunoassay applications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-01 00:00
Share Issue/Capital Change
전환청구권행사
Korean 8.6 KB
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 881.8 KB
2025-08-14 00:00
Capital/Financing Update
파생상품거래손실발생
Korean 5.8 KB
2025-08-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 80.3 KB
2025-07-17 00:00
Share Issue/Capital Change
전환청구권행사
Korean 8.6 KB
2025-07-15 00:00
Share Issue/Capital Change
전환청구권행사
Korean 8.5 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]수시공시의무관련사항(공정공시) (유상증자 계획)
Korean 11.4 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 960.9 KB
2025-03-28 00:00
AGM Information
정기주주총회결과
Korean 24.1 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 26.0 KB
2025-03-20 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.4 MB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 167.0 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.4 KB
2025-03-12 00:00
Legal Proceedings Report
파생상품거래손실발생
Korean 6.8 KB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 13.9 KB

Automate Your Workflow. Get a real-time feed of all QuantaMatrix Incorporated filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for QuantaMatrix Incorporated

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for QuantaMatrix Incorporated via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

FutureChem Co., Ltd. Logo
Develops radiopharmaceuticals & diagnostic agents for cancer, Alzheimer's, and Parkinson's disease.
South Korea
220100
Future Medicine  Co., Ltd. Logo
Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.
South Korea
341170
Develops long-acting injectable therapies for chronic diseases and cancer.
South Korea
456160
Gabather AB Logo
Developing novel GABAA receptor drugs for neuropsychiatric disorders.
Sweden
GABA
Gain Therapeutics, Inc. Logo
Using an AI platform to develop allosteric therapies for neurodegenerative diseases.
United States of America
GANX
Galapagos NV Logo
Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.
Belgium
GLPG
Galderma Group AG Logo
A pure-play dermatology company with aesthetics, skincare, and therapeutic solutions.
Switzerland
GALD
GALECTIN THERAPEUTICS INC Logo
Developing galectin-3 inhibitors for MASH cirrhosis, fibrosis, and cancer.
United States of America
GALT
Galecto, Inc. Logo
Develops novel small molecule drugs targeting cancer and severe fibrotic diseases.
United States of America
GLTO
Galmed Pharmaceuticals Ltd. Logo
Develops oral therapeutics for liver, metabolic, and inflammatory diseases like NASH.
United States of America
GLMD

Talk to a Data Expert

Have a question? We'll get back to you promptly.